Drug Trial Radar · NCT07672769
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2027
Study completion Dec 2030
Sponsor
- Lead sponsor
- Faron Pharmaceuticals LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase IIb study (BEXERA) will evaluate the safety and efficacy of bexmarilimab (FP-1305), an antibody targeting Clever-1, given in combination with azacitidine compared with azacitidine plus placebo in adults with treatment-naïve higher-risk myelodysplastic syndromes (HR-MDS). Participants will be randomized to receive bexmarilimab at one of two dose levels (1 mg/kg or 3 mg/kg) plus azacitidine, or placebo plus azacitidine. The primary aim is to select the recommended dose of bexmarilimab for subsequent development based on a predefined integration of clinical response and safety/tolerability.
Conditions
- Higher Risk Myelodysplastic Syndromes
Interventions
bexmarilimab (1mg/kg)Drug
1mg/kg. Administered weekly (Q1W) with the opportunity to reduce frequency to biweekly (Q2W) based on time on treatment and disease response. Intravenous (IV) administration
azacitidineDrug
Standard of care medication, administered per institutional guidelines/label
PlaceboDrug
Participants will receive saline placebo, prepared by the local site pharmacy to match bexmarilimab at point of dispensation. Administered on a schedule to match bexmarilimab
bexmarilimab (3mg/kg)Drug
3mg/kg. Administered weekly (Q1W) with the opportunity to reduce frequency to biweekly (Q2W) based on time on treatment and disease response. Intravenous (IV) administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose selection utility score utilising efficacy and safety components.Time frame: 3-4 months from last participant enrollment
Locations
35 sites in 7 countries. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Not yet recruiting
Yale Cancer Center
New Haven, Connecticut · Not yet recruiting
Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System
Pembroke Pines, Florida · Not yet recruiting
Mass General Brigham Cancer Institute
Boston, Massachusetts · Not yet recruiting
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina · Not yet recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Not yet recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
Medical College of Wisconsin - Clinical Cancer Center - Froedtert Hospital
Milwaukee, Wisconsin · Not yet recruiting
Fakultní nemocnice Brno
Brno, Czechia · Not yet recruiting
Fakultní nemocnice Hradec Králové
Hradec Králové, Czechia · Not yet recruiting
Fakultni nemocnice Ostrava
Ostrava-Poruba, Czechia · Not yet recruiting
Ustav hematologie a krevni transfuze
Prague, Czechia · Not yet recruiting
Vseobecna fakultni nemocnice v Praze
Prague, Czechia · Not yet recruiting
Helsinki University Hospital Comprehensive Cancer Center
Helsinki, Finland · Not yet recruiting
Oulu University Hospital
Oulu, Finland · Not yet recruiting
Tampere University Hospital
Tampere, Finland · Not yet recruiting
Turku University Hospital
Turku, Finland · Not yet recruiting
CHU de Bordeaux
Bordeaux, France · Not yet recruiting
Hôpital Saint-Louis
Paris, France · Not yet recruiting
CHU de Poitiers
Poitiers, France · Not yet recruiting
The Institut Gustave Roussy
Villejuif, France · Not yet recruiting
AOU SS. Antonio e Biagio e Cesare Arrigo
Alessandria, Italy · Not yet recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy · Not yet recruiting
INOC - Istituto Nazionale Oncologico Candiolo
Candiolo, Italy · Not yet recruiting
IRCCS Istituto Europeo di Oncologia
Milan, Italy · Not yet recruiting
Pratia Onkologia Katowice
Katowice, Poland · Not yet recruiting
Aidport Clinical Trials Hospital
Skórzewo, Poland · Not yet recruiting
MTZ Clinical Research Powered by Pratia
Warsaw, Poland · Not yet recruiting
University Hospital Birmingham Nhs Trust
Birmingham, United Kingdom · Not yet recruiting
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom · Not yet recruiting
Royal Cornwall Hospitals NHS Trust
Truro, United Kingdom · Recruiting
King's College Hospital
London, Greater London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom · Recruiting
Maidstone and Tunbridge Wells NHS Trust
Maidstone, Kent, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.